A clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential – Sequella, Inc. – has just received Fast Track Designation from the USFDA for SQ109.
Currently undergoing Phase 1 clinical trial on US IND (investigational new drug) application, SQ109 is Sequella, Inc.’s proprietary lead drug candidate for the treatment of pulmonary tuberculosis (TB).
SQ109 is an orally active small molecule antibiotic that inhibits cell wall synthesis and acts on multiple cellular pathways in a select group of microorganisms, including Mycobacterium tuberculosis, the bacteria that cause TB. SQ109 enhances, both in vitro and in vivo, the activity of the anti- tubercular drugs isoniazid and rifampin, thereby shortening by 25% the time required to cure mice of experimental TB.According to Dr. Carol Nacy, CEO of Sequella:
Find more details from the press release (a pdf file)"This FDA Fast Track designation validates SQ109 as a potentially unique addition to the TB therapeutic armamentarium. This is an important regulatory milestone and recognition that SQ109 may address unmet needs in TB therapy to improve and shorten the current treatment regimen."
Comment Preview